Bronchopulmonary Dysplasia Clinical Trial
— PICTUREOfficial title:
Pulmonary Magnetic Resonance Imaging of Ex-preterm Children With and Without Bronchopulmonary Dysplasia To Understand Risk of Emphysematous Changes (PICTURE)
Verified date | July 2020 |
Source | Children's Hospital of Eastern Ontario |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Health Issue: Bronchopulmonary dysplasia (BPD), a chronic lung disease, is the most common
complication of being born premature. Damage to the still developing lung stops the normal
formation of the alveoli. Young adults with a history of BPD have lower lung function, early
heart disease, and increased risk of death, compared to those without BPD. Recently, it has
been reported that they may also develop a type of lung disease typically seen in older
adults with a longstanding history of smoking. The severity of lung disease is usually
measured using pulmonary function tests (PFT), but these tests may be normal, even in the
presence of important changes in the fine structure of the lung. Such structural changes may
be early markers of future lung disease and can be detected using lung magnetic resonance
imaging (MRI). Unlike other ways of imaging the lungs, MRI does not expose people to harmful
X-rays. To date, no studies have been done to examine the fine structure of the lung of
school-aged children who had a history of BPD, to determine whether there are signs of lung
disease that might not otherwise be obvious. This is important because once armed with this
information, preventive measures can be taken to avoid worsening of lung disease.
Objective: 1) In 7-9 year-old children born extremely premature, lung MRI will be compared
between those with and without BPD. The Investigators expect to observe more severe
structural lung abnormalities in children with BPD, compared to those without BPD; 2) The
Investigators will test to see if children with more severe MRI abnormalities also have worse
lung function, and/or more symptoms of breathing problems. The Investigators expect to
observe more PFT abnormalities in children with BPD than in those without and that these will
match up with lung fine structure abnormalities identified on MRI.
How will work be undertaken? Children 7-9 years old who were born extremely prematurely will
be recruited to participate in this study. Participants will be identified from Neonatal
Follow-up clinics they attended. The Investigators will enroll 20 children with BPD and 20
without BPD. Participants will have lung MR images taken, during which they need to lie still
for a few minutes. PFT will also be performed, during which they will blow into a machine.
Parents will be asked to complete questionnaires about breathing problems, their living
conditions (environment) and any doctor visits or hospital stays. Medical charts will be
reviewed for information about their birth.
Unique/Innovative Aspects: This will be the first study using MRI as an innovative way to
visualize and measure fine structure of the lung in children born prematurely with and
without BPD. These findings may be early markers of lung disease, which would identify
children who have, or are at risk of developing lung disease later in life, for whom the
Investigators may be able to offer treatments now and/or prevent worsening of lung disease.
Status | Completed |
Enrollment | 45 |
Est. completion date | September 18, 2019 |
Est. primary completion date | September 18, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 7 Years to 9 Years |
Eligibility |
Inclusion Criteria: - Inclusion Criteria: Children born pre-term at less than 28 weeks' gestation, currently aged 7-9 years, with and without BPD will be included. Exclusion Criteria: - Children with known interstitial lung disease, congenital lung anomalies, cystic fibrosis, ciliary dysfunction, immunodeficiency, neuromuscular disease or structural heart disease, which may have associated PFT and/or MRI findings; - Genetic syndromes which may have other associated structural lung anomalies; - Any contraindications for MRI; - Severe neurosensory deficits which would prevent test completion; - Viral or bacterial respiratory infection within 6 weeks.50 |
Country | Name | City | State |
---|---|---|---|
Canada | CHU-Sainte Justine | Montreal | Quebec |
Canada | Children's Hospital of Eastern Ontario | Ottawa | Ontario |
Canada | The Children"s Hospital of Eastern Ontario | Ottawa | Ontario |
Canada | Hospital for Sick Children | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
Children's Hospital of Eastern Ontario |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Primary Outcome: MRI-derived Pulmonary Microstructure measurements | Images will be acquired in 10-15 seconds in all subjects using a 2D radial ultra-short echo time pulse sequence, to quantify signal intensity as a surrogate of parenchymal tissue density. Subjects will be asked to breath normally and then inhale a fixed volume of air from functional residual capacity (the volume of which is calibrated to 50% of inspiratory capacity) and hold their breath while images are acquired, as previously described. The pulse sequence for imaging will be developed as previously described and validated for the different MR scanner platforms at the three participating sites, through the Imaging platform of the Canadian Respiratory Research Network. All image volumes will be scaled to functional residual capacity plus 50% of inspiratory capacity and will be acquired in breath-hold at that inspiratory volume. The CRRN Imaging platform will also provide test objects for calibration of 1H MRI signal intensity to ensure | Assessed at one time point at Baseline | |
Secondary | Height | Height and weight will be measured at baseline prior to doing the Pulmonary Function Testing. It is important to have current measurements of Height and weight as they are used in the calculation of some of the variables that are measured during PFTs | Assessed at one time point at Baseline | |
Secondary | Weight | Height and weight will be measured at baseline prior to doing the Pulmonary Function Testing. It is important to have current measurements of Height and weight as they are used in the calculation of some of the variables that are measured during PFTs | Assessed at one time point at Baseline | |
Secondary | Airflow limitations | Outcomes related to airflow limitation, including FEV1, was selected as it has been shown in previous studied to be reduced in children and adults with a history of prematurity and BPD, | Assessed at one time point at Baseline | |
Secondary | Airflow limitations | Outcomes related to airflow limitation, including FEV1/FVC was selected as it has been shown in previous studied to be reduced in children and adults with a history of prematurity and BPD, | Assessed at one time point at Baseline | |
Secondary | Airflow limitations | Outcomes related to airflow limitation, including mid-expiratory flows (FEF), was selected as it has been shown in previous studied to be reduced in children and adults with a history of prematurity and BPD, | Assessed at one time point at Baseline | |
Secondary | Spirometry pre and post bronchodilators | Spirometry pre and post bronchodilators, lung volumes will be performed on all participants, according to established American Thoracic Society criteria for test performance and scoring. Published predictive equations for spirometry, lung volumes and DLCO will be used. Lung volumes, assessed by TLC, RV and RV/TLC ratio, will be used to identify gas trapping and will be correlated with gas trapping and ventilation inhomogeneity on MRI. | Assessed at one time point at Baseline | |
Secondary | Lung Volumes - Total Lung Capacity | Spirometry pre and post bronchodilators, lung volumes will be performed on all participants, according to established American Thoracic Society criteria for test performance and scoring. Published predictive equations for spirometry, lung volumes and DLCO will be used. Lung volumes, assessed by TLC, RV and RV/TLC ratio, will be used to identify gas trapping and will be correlated with gas trapping and ventilation inhomogeneity on MRI. | Assessed at one time point at Baseline | |
Secondary | Lung Volumes - Residual Volume | Spirometry pre and post bronchodilators, lung volumes will be performed on all participants, according to established American Thoracic Society criteria for test performance and scoring. Published predictive equations for spirometry, lung volumes and DLCO will be used. Lung volumes, assessed by TLC, RV and RV/TLC ratio, will be used to identify gas trapping and will be correlated with gas trapping and ventilation inhomogeneity on MRI. | Assessed at one time point at Baseline | |
Secondary | Lung Volumes - RV/TLC ratio | Spirometry pre and post bronchodilators, DLco will be performed on all participants, according to established American Thoracic Society criteria for test performance and scoring. Published predictive equations for spirometry, lung volumes and DLCO will be used. Lung volumes, assessed by TLC, RV and RV/TLC ratio, will be used to identify gas trapping and will be correlated with gas trapping and ventilation inhomogeneity on MRI. | Assessed at one time point at Baseline | |
Secondary | DLCO | Spirometry pre and post bronchodilators, DLco will be performed on all participants, according to established American Thoracic Society criteria for test performance and scoring. Published predictive equations for spirometry, lung volumes and DLCO will be used. Lung volumes, assessed by TLC, RV and RV/TLC ratio, will be used to identify gas trapping and will be correlated with gas trapping and ventilation inhomogeneity on MRI. | Assessed at one time point at Baseline | |
Secondary | Diffusion capacity | Diffusion capacity was included as an outcome, as this may be a sensitive marker of alveolar simplification, a hallmark of the "new" BPD. | Assessed at one time point at Baseline | |
Secondary | Medical History | Additional information necessary to describe the population's obstetrical and neonatal history will be obtained from data already abstracted in the Canadian Neonatal Network database, which covers the time frame of birth to the present time, to which all centers have access, and through review of the medical charts, including: (1) Maternal data: prenatal corticosteroids, chorioamnionitis; (b) Neonatal data: gestational age, birth weight, APGAR, respiratory-related treatment (surfactant, mechanical ventilation, oxygen, steroids), medical complications (sepsis, patent ductus). | Assessed once from the Canadian Neonatal Network database | |
Secondary | ATS-DLD-78-c | A validated questionnaire (ATS-DLD-78-c) will be administered to collect information on respiratory symptoms and the following determinants of health: (1) Socio-economic status, occupation and education level of parents. (2) Family history of chronic pulmonary diseases; (3) Environmental exposures: cigarette smoke, pets, wood stove, daycare/school, living quarters; (4) Personal medical history: hospitalization for respiratory-related illness and current medication use. | Assessed at one time point at Baseline | |
Secondary | MODIFIED EPWORT SLEEPINESS SCALE | On the night of the sleep study the patients will be provided with a sleep questionnaire designed to elicit a history of sleep-disordered breathing, Excessive daytime sleepiness is considered present if the Epworth score is = 11.14 | Assessed at one time point at Baseline | |
Secondary | Pediatric Sleep Questionnaire (Chervin); | On the night of the sleep study the patients will be provided with a sleep questionnaire (developed by Chervin et al) designed to elicit a history of sleep-disordered breathing, SDB will be considered present if 8 of Chervin's questions are positive. | Assessed at one time point at Baseline | |
Secondary | The Habitual Activity Estimation Scale (HAES) | The HAES questionnaire will be administered at baseline to assess the level of physical activity of the child. This validated questionnaire has been used in many clinical populations of children(149;150) and captures both the duration and intensity of physical activity.(151;152) Information is completed on one typical weekday and one weekend day. The questionnaire takes approximately 15 minutes to complete. | Assessed at one time point at Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04506619 -
Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants
|
||
Completed |
NCT04936477 -
Ventilation-perfusion (V/Q) Ratio and Alveolar Surface Area in Preterm Infants
|
N/A | |
Recruiting |
NCT05285345 -
Implementation of a Consensus-Based Discharge Protocol for Preterm Infants With Lung Disease
|
||
Completed |
NCT03649932 -
Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing
|
Phase 1 | |
Terminated |
NCT02524249 -
Early Versus Late Caffeine for ELBW Newborns
|
N/A | |
Completed |
NCT02249143 -
Duration of Continuous Positive Airway Pressure and Pulmonary Function Testing in Preterm Infants
|
N/A | |
Active, not recruiting |
NCT01632475 -
Follow-Up Study of Safety and Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia
|
||
Completed |
NCT01460576 -
Improving Prematurity-Related Respiratory Outcomes at Vanderbilt
|
N/A | |
Unknown status |
NCT00254176 -
Cysteine Supplementation in Critically Ill Neonates
|
Phase 2/Phase 3 | |
Completed |
NCT00419588 -
Growth of Airways and Lung Tissues in Premature and Healthy Infants
|
||
Completed |
NCT00208039 -
Pilot Trial of Surfactant Booster Prophylaxis For Ventilated Preterm Neonates
|
N/A | |
Completed |
NCT00319956 -
Trial II of Lung Protection With Azithromycin in the Preterm Infant
|
Phase 2 | |
Completed |
NCT00006401 -
Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants
|
Phase 3 | |
Terminated |
NCT05030012 -
Maintaining Optimal HVNI Delivery Using Automatic Titration of Oxygen in Preterm Infants
|
N/A | |
Completed |
NCT00006058 -
Study of the Pathobiology of Bronchopulmonary Dysplasia in Newborns
|
N/A | |
Completed |
NCT00005376 -
Premature Birth and Its Sequelae in Women
|
N/A | |
Completed |
NCT00011362 -
Dexamethasone Therapy in VLBW Infants at Risk of CLD
|
Phase 3 | |
Completed |
NCT00004805 -
Study of the Effect of Four Methods of Cardiopulmonary Resuscitation Instruction on Psychosocial Response of Parents With Infants at Risk of Sudden Death
|
N/A | |
Completed |
NCT05152316 -
The Baby Lung Study
|
||
Recruiting |
NCT04821453 -
NAVA vs. CMV Crossover in Severe BPD
|
N/A |